Meeting on the Med 2021 and Cell Therapy View overview page

4:25
Building the advanced therapies workforce in the UK
Matthew Durdy • 9 Apr 2021
3:31
The state of investment in cell & gene therapy
Matthew Durdy • 9 Apr 2021
3:41
Improving patient access to advanced therapies: are we ready for them?
Durhane Wong-Rieger • 6 Apr 2021
2:58
ATA188 in EBV+ progressive multiple sclerosis
Pascal Touchon • 7 Apr 2021
2:56
International collaboration in advanced therapies
Amy DuRoss • 8 Apr 2021
2:48
Supply chain management & automation
Amy DuRoss • 8 Apr 2021
2:45
What can the field learn from the COVID-19 pandemic?
Amy DuRoss • 8 Apr 2021
1:14
The importance of specialty medical centers in delivering ATMPs
Paige Bischoff • 11 Mar 2021
4:06
Shaping the future of CMC in cell & gene therapy
Stephen Ward • 14 Apr 2021
3:24
Advancing the sector: training, scalability & materials standardization
Stephen Ward • 14 Apr 2021
3:43
Horizon scanning for the UK cell & gene therapy sector
Stephen Ward • 14 Apr 2021
3:10
The lasting impact of COVID-19 on the CGT sector
Stephen Ward • 14 Apr 2021
3:06
Targeting solid tumors: SPEAR T-cells & HLA-independent TCRs
Jo Brewer • 7 Apr 2021
1:09
SPEARHEAD-1: ADP-A2M4 in synovial sarcoma and MRCLS
Jo Brewer • 7 Apr 2021
1:22
SURPASS: evaluating the next-generation of SPEAR T-cell therapy
Jo Brewer • 7 Apr 2021
4:23
Off-the-shelf iPSC therapies for solid tumors
Jo Brewer • 7 Apr 2021
The content of VJRegenMed is intended for healthcare professionals